A Study in Healthy Men to Test How BI 1569912 is Processed in the Body
Фаза 1
Завершено
NCT06520553
| Заболевание | Healthy |
|---|
| Фаза | Фаза 1 |
|---|
| Спонсор | Boehringer Ingelheim |
|---|
| Статус | Завершено |
|---|
| Участники | 8 участн. |
|---|
| Вмешательство | BI 1569912 (C-14), BI 1569912 (C-13) |
|---|
| Дата начала | 26.08.2024 |
|---|
| Дата завершения | 3.10.2024 |
|---|
| Публикация результатов | 22.05.2026 |
|---|
Кратко
The main objectives of this trial are: * To investigate basic pharmacokinetics of BI 1569912 and total radioactivity, including mass balance, excretion pathways and metabolism following oral administration of BI 1569912 (C-14) to healthy male subjects (test treatment, T). * To investigate the absolute bioavailability of BI 1569912 as single oral solution dose, using a single, concomitant intravenous micro-tracer administration of BI 1569912 (C-13) (reference treatment, R)
Fraction Excreted in Urine as Percentage of the Administered Dose Over the Time Interval From 0 to the Last Quantifiable Time Point (fe Urine,0-tz) of [14C]-Radioactivity
Up to 14 days. · Percentage of administered dose
| 10 Milligram (mg) BI 1569912 (C-14) Oral Solution (Test Treatment) | 57.0 ± 10.9 Percentage of administered dose |
|---|
Fraction Excreted in Faeces as Percentage of the Administered Dose Over the Time Interval From 0 to the Last Quantifiable Time Point (fe Faeces,0-tz) of [14C]-Radioactivity
Up to 14 days. · Percentage of administered dose
| 10 Milligram (mg) BI 1569912 (C-14) Oral Solution (Test Treatment) | 31.1 ± 62.9 Percentage of administered dose |
|---|
Total Recovery of [14C]-Radioactivity
Up to 14 days. · Percentage of administered dose
| 10 Milligram (mg) BI 1569912 (C-14) Oral Solution (Test Treatment) | 91.2 ± 12.7 Percentage of administered dose |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.